Table of Contents
ISRN Pharmacology
Volume 2011 (2011), Article ID 314209, 11 pages
http://dx.doi.org/10.5402/2011/314209
Research Article

Novel Phenazine 5,10-Dioxides Release OH in Simulated Hypoxia and Induce Reduction of Tumour Volume In Vivo

1Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, 11400 Montevideo, Uruguay
2Cátedra de Análisis Clínicos, Laboratorio Central—Hospital Maciel (Ministerio de Salud Pública), Facultad de Química, Universidad de la República, 11200 Montevideo, Uruguay
3Departamento de Patobiología, Facultad de Veterinaria, Universidad de la República, 11600 Montevideo, Uruguay
4Department of Biochemistry and Molecular Biology, Faculty of Biology, Institute of Biomedicine of University of Barcelona (IBUB) and IDIBAPS, Unit Associated with CSIC, 08028 Barcelona, Spain
5Departamento de Química Inorgánica y Analítica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, 83800005 Santiago, Chile
6Centro de Investigaciones en Farmacobiología Aplicada, Universidad de Navarra, 31008 Pamplona, Spain

Received 16 February 2011; Accepted 14 April 2011

Academic Editor: P. Cos

Copyright © 2011 María L. Lavaggi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Brown and W. R. Wilson, “Exploiting tumour hypoxia in cancer treatment,” Nature Reviews Cancer, vol. 4, no. 6, pp. 437–447, 2004. View at Google Scholar · View at Scopus
  2. L. Zhang and R. P. Hill, “Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis,” Cancer Research, vol. 64, no. 12, pp. 4180–4189, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Ruan, G. Song, and G. Ouyang, “Role of hypoxia in the hallmarks of human cancer,” Journal of Cellular Biochemistry, vol. 107, no. 6, pp. 1053–1062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. Denny, “The role of hypoxia-activated prodrugs in cancer therapy,” Lancet Oncology, vol. 1, no. 1, pp. 25–29, 2000. View at Google Scholar · View at Scopus
  5. Q. T. Le, AL. Taira, S. Budenz et al., “Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas,” Cancer, vol. 106, no. 9, pp. 1940–1949, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. Q. T. X. Le, J. Moon, M. Redman et al., “Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222,” Journal of Clinical Oncology, vol. 27, no. 18, pp. 3014–3019, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Daniels and K. S. Gates, “DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): evidence for involvement of hydroxyl radical,” Journal of the American Chemical Society, vol. 118, no. 14, pp. 3380–3385, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Gallagher, C. M. Hughes, M. M. Murray et al., “The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N,” British Journal of Cancer, vol. 85, no. 4, pp. 625–629, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Cerecetto, M. González, MA. L. Lavaggi, A. Azqueta, A. López De Cerain, and A. Monge, “Phenazine 50-dioxide derivatives as hypoxic selective cytotoxins,” Journal of Medicinal Chemistry, vol. 48, no. 1, pp. 21–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Cerecetto, M. González, M. L. Lavaggi et al., “Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins—part II: structure-activity relationship studies,” Medicinal Chemistry, vol. 2, pp. 511–521, 2006. View at Google Scholar
  11. M. L. Lavaggi, M. Cabrera, M. D. L. A. Aravena et al., “Study of benzo[a]phenazine 72-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation,” Bioorganic and Medicinal Chemistry, vol. 18, no. 12, pp. 4433–4440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. L. Lavaggi, M. Nieves, M. Cabrera et al., “Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins,” European Journal of Medicinal Chemistry, vol. 45, pp. 5362–5369, 2010. View at Google Scholar
  13. O. G. Pachón, A. Azqueta, M. L. Lavaggi et al., “Antitumoral effect of phenazine N5,N10-dioxide derivatives on Caco-2 cells,” Chemical Research in Toxicology, vol. 21, no. 8, pp. 1578–1585, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Lavaggi, M. Cabrera, M. González, and H. Cerecetto, “Differential enzymatic reductions governing the differential hypoxia-selective cytotoxicities of phenazine 50-dioxides,” Chemical Research in Toxicology, vol. 21, no. 9, pp. 1900–1906, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Azqueta, L. Arbillaga, G. Pachón, M. Cascante, E. E. Creppy, and A. L. D. Cerain, “A quinoxaline 1,4-di-N-oxide derivative induces DNA oxidative damage not attenuated by vitamin C and E treatment,” Chemico-Biological Interactions, vol. 168, no. 2, pp. 95–105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. D. B. Morton and P. H. Griffiths, “Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment,” Veterinary Record, vol. 116, no. 16, pp. 431–436, 1985. View at Google Scholar · View at Scopus
  17. B. T. Mossman, “In vitro approaches for determining mechanisms of toxicity and carcinogenicity by asbestos in the gastrointestinal and respiratory tracts,” Environmental Health Perspectives, vol. 53, pp. 155–161, 1983. View at Google Scholar · View at Scopus
  18. C. Lozano, J. L. Torres, L. Julià, A. Jimenez, J. J. Centelles, and M. Cascante, “Effect of new antioxidant cysteinyl-flavanol conjugates on skin cancer cells,” FEBS Letters, vol. 579, no. 20, pp. 4219–4225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Monge, F. J. Martínez-Crespo, A. López De Ceráin et al., “Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-Di-N-oxides. 2,” Journal of Medicinal Chemistry, vol. 38, no. 22, pp. 4488–4494, 1995. View at Google Scholar · View at Scopus
  20. T. A. Thompson, J. D. Haag, and M. N. Gould, “Ras gene mutations are absent in NMU-induced mammary carcinomas from aging rats,” Carcinogenesis, vol. 21, no. 10, pp. 1917–1922, 2000. View at Google Scholar · View at Scopus
  21. M. T. Beck, N. Y. Chen, K. J. Franek, and W. Y. Chen, “Experimental therapeutics prolactin antagonist-endostatin fusion protein as a targeted dual functional therapeutic agent for breast cancer,” Cancer Research, vol. 63, pp. 3598–3604, 2003. View at Google Scholar
  22. A. Collins, M. Dušinská, M. Franklin et al., “Comet assay in human biomonitoring studies: reliability, validation, and applications,” Environmental and Molecular Mutagenesis, vol. 30, no. 2, pp. 139–146, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. A. R. Collins, S. J. Duthie, and V. L. Dobson, “Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA,” Carcinogenesis, vol. 14, no. 9, pp. 1733–1735, 1993. View at Google Scholar · View at Scopus
  24. A. Carr and B. Frei, “Does vitamin C act as a pro-oxidant under physiological conditions?” FASEB Journal, vol. 13, no. 9, pp. 1007–1024, 1999. View at Google Scholar · View at Scopus
  25. L. L. Herscher, M. C. Krishna, J. A. Cook et al., “Protection against SR 4233 (tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron,” International Journal of Radiation Oncology Biology Physics, vol. 30, no. 4, pp. 879–885, 1994. View at Google Scholar · View at Scopus
  26. L. D. McPhail and S. P. Robinson, “Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis,” Radiology, vol. 254, no. 1, pp. 110–118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Aguirre, M. Boiani, H. Cerecetto et al., “Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies,” Pharmazie, vol. 61, no. 1, pp. 54–59, 2006. View at Google Scholar · View at Scopus